Biomerica Inc

Biomerica Inc., a Newport Beach medical products company, said Monday that it has launched a new online drugstore, TheBigRx.com, which features drugstore products and health information. In a press release, Biomerica said it plans to add a pharmacy for online prescription orders.

Biomerica Inc. said Tuesday that it has received Food and Drug Administration clearance to market a nonradioactive test to detect and monitor certain thyroid diseases. The company develops, manufactures and markets diagnostic products for clinical labs, physician offices and home self-testing.

Biomerica Inc., a Newport Beach maker of medical diagnostic products, said Tuesday it signed a two-year exclusive agreement with Sentinel CH, an Italian medical diagnostic product distributor, to market and distribute Biomerica's Allerquant Med90 food allergy kit in Italy. Financial terms weren't disclosed. Biomerica's stock slipped 6 cents a share to $3.09 in Nasdaq trading.

Biomerica Inc.: The Newport Beach provider of diagnostic products for early detection of diseases posted a loss of $170,415, or 4 cents a share, for the fiscal third quarter ended Feb. 28, compared with net income of $25,755, or 1 cent a share, a year earlier. Revenue declined 14% to $1.8 million from $2.1 million. The company attributed the revenue decrease to lower foreign sales.

Biomerica Inc., a Newport Beach manufacturer of medical diagnostic products, reported a net loss of $72,548, or 2 cents a share, for the fiscal year ended May 31, contrasted with net income of $141,432, or 3 cents a share, for the previous year. Sales declined 7% to $8.7 million. The company attributed the sales drop to a decline in sales to foreign distributors.

Biomerica Inc., a Newport Beach manufacturer of medical diagnostic products, reported that net income for the fiscal year dropped to $141,432, or 3 cents a share, from $446,845, or 11 cents a share, for the previous year. Revenue for the year ended May 31 rose 2% to $9.4 million from $9.2 million. The company said the decline in net income was due primarily to a 96% increase in new product development expenditures.

Biomerica Inc., a maker of advanced medical diagnostic products, said Wednesday that it has received clearance from the U.S. Food and Drug Administration to market a test to detect and monitor certain thyroid diseases. The new nonradioactive enzyme immunoassay test detects Triiodothyronine (T3), a key hormone produced by the thyroid gland responsible for, among other functions, regulating the use of calories in basic metabolism.